National Health Act 1953 - Amendment determination under subsections 85A(1) and (2) and 88(1C) - Prescription of pharmaceutical benefits by authorised optometrists (No. PB 27 of 2009)

Overview

The National Health Act 1953, as amended by the legislative instrument PB 27 of 2009, seeks to ensure that Australians have reliable, timely, and affordable access to a wide range of medicines through the Pharmaceutical Benefits Scheme (PBS). The amendments made by this instrument, which commenced on 1 April 2009, were designed to reflect the recommendations of the Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body that advises on the availability of pharmaceutical benefits. The PBAC considers factors such as the medical conditions for which a medicine has been approved, its clinical effectiveness, safety, and cost-effectiveness compared to other treatments. This legislative instrument amends previous determinations under subsections 85A(1) and (2), and 88(1C) of the Act, which govern the form or forms of pharmaceutical benefits that may be prescribed, the maximum quantity or number of units that may be directed to be supplied in one prescription, and the manner of administration that may be specified in a prescription. The amendments include changes to the listed drug names, descriptions of form, and brand names for certain medications, as detailed in Schedule 1 of the instrument.

Scope and Application

The National Health Act 1953, as amended by the legislative instrument numbered PB 27 of 2009, pertains to the Pharmaceutical Benefits Scheme (PBS) under which the Commonwealth ensures Australians have reliable, timely, and affordable access to a wide range of medicines. The Act applies to pharmaceutical benefits, which are defined in subsection 84(1) and include listed drugs and certain extemporaneously-prepared medicinal preparations. These are declared by the Minister through legislative instruments under subsection 85(2). The Act further applies to the determination of the forms of listed drugs, their administration, and the brands that are recognised under the scheme. The Minister can determine these aspects under subsections 85(3) to 85(6), with further specifications for prescription forms and quantities available under subsections 85A(1) and (2), and 88(1C). This Act has a national jurisdictional reach, governing the supply and prescription of pharmaceutical benefits across Australia. The legislative instrument, effective from 1 April 2009, amends earlier determinations and includes changes to the description of a listed drug, specifically altering its form and brand name as detailed in Schedule 1.

Key Provisions

The National Health Act 1953 (the Act) establishes the Pharmaceutical Benefits Scheme (PBS), which ensures that all Australians have access to reliable, timely, and affordable medicines. The key provisions of this legislation, particularly those related to the PBS, are found in Part VII, with subsections 85A(1) and (2) and 88(1C) being particularly relevant. Subsection 85(1) specifies that the Commonwealth provides benefits for pharmaceutical items in accordance with the Act, while subsection 85(2) allows the Minister to declare by legislative instrument which drugs and medicinal preparations are listed drugs. Subsection 85A(1) and (2) authorise the Minister to determine the form and manner of administration of pharmaceutical benefits, and the specifics of prescriptions for these benefits, respectively. Section 88(1C) allows the Minister to determine the pharmaceutical benefits for which an optometrist is authorised to write a prescription. These provisions are integral to governing the PBS and ensuring that the scheme operates effectively. The Act imposes several obligations on the parties involved. The Minister is responsible for determining the forms and administration methods of pharmaceutical benefits and the specifics of prescriptions, as well as authorising optometrists to prescribe certain pharmaceutical benefits. The Pharmaceutical Benefits Advisory Committee (PBAC) plays a crucial role by recommending which drugs and medicinal preparations should be available as pharmaceutical benefits. The PBAC is composed of members from various fields, including consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists, and specialists. When making recommendations, the PBAC considers the medical conditions for which a medicine has been approved for use in Australia, its clinical effectiveness, safety, and cost-effectiveness compared with other treatments. These obligations ensure a comprehensive and expert-driven approach to managing the PBS. There are potential consequences for non-compliance with the Act. While the Act itself does not specify penalties for breaches, breaches of related regulations or legislative instruments may result in administrative, civil, or criminal penalties. For example, offences under the Therapeutic Goods Act 1989 may incur penalties, including fines and imprisonment. Similarly, breaches of specific regulations made under the National Health Act could result in penalties as outlined in those regulations. It is essential for all parties involved to adhere to the provisions and determinations made under the Act to avoid any legal repercussions. In summary, the key provisions of the National Health Act 1953, particularly subsections 85A(1) and (2) and 88(1C), establish the framework for the Pharmaceutical Benefits Scheme. The Minister and the PBAC have specific roles in determining the forms, administration methods, and prescription specifics of pharmaceutical benefits. The Act ensures that the PBS operates effectively by providing reliable, timely, and affordable access to medicines for all Australians. Compliance with the Act and its related regulations is crucial to avoid any legal consequences that may arise from non-compliance.